Condition (MeSH)
Thrombasthenia
ClinicalTrials.gov lists 19 trials for Thrombasthenia or a narrower condition beneath it. Novo Nordisk A/S has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 19 trials are tagged with Thrombasthenia itself; the rest are tagged with a narrower condition beneath it.
When did Thrombasthenia trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 3 |
| 2010 | 1 |
| 2008 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Thrombasthenia trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Not applicable | 5 |
| Observational | 8 |
How many Thrombasthenia trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 9 |
| Terminated | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Thrombasthenia trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novo Nordisk A/S | 4 |
| American Thrombosis and Hemostasis Network | 1 |
| AryoGen Pharmed Co. | 1 |
| Catalyst Biosciences | 1 |
| Hemab ApS | 1 |
Which drugs are being tested for Thrombasthenia? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| activated recombinant human factor VII | 5 |
| Concizumab | 1 |
| Cytoxan | 1 |
| Alefacept | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| HMB-001 | 1 |
| Antibodies screening | 1 |
| Coagulation Factor VIIa variant | 1 |
| Abatacept SC | 1 |
| Reduced Toxicity Ablative Regimen | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Thrombasthenia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Chronic graft versus host disease | 2 | 1 |
| Infections and infestations - Other, specify | 2 | 1 |
| Sepsis | 2 | 1 |
| Stomatitis | 2 | 1 |
| Febrile neutropenia | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Thrombasthenia? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study. | Journal of thrombosis and haemostasis : JTH | 2024 | Yes |
| The Glanzmann Thrombasthenia Registry: safety of platelet therapy in patients with Glanzmann thrombasthenia and changes in alloimmunization status. | Haematologica | 2023 | Yes |
| Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy. | Haematologica | 2021 | Yes |
| A Glanzmann thrombasthenia family associated with a TUBB1-related macrothrombocytopenia. | Journal of thrombosis and haemostasis : JTH | 2019 | Yes |
| Clinical and molecular insights into Glanzmann's thrombasthenia in China. | Clinical genetics | 2018 | Yes |
Showing 5 of 17 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.